Drug and Alcohol Services South Australia, Adelaide, Australia.
Department of Gastroenterology, Flinders University, Adelaide, Australia.
Drug Alcohol Rev. 2018 Sep;37(6):731-737. doi: 10.1111/dar.12809. Epub 2018 May 2.
This study aimed to compare complications arising due to the supratherapeutic use of paracetamol/codeine or ibuprofen/codeine containing compound analgesics in primary codeine-dependent patients presenting to a drug and alcohol withdrawal service. Data was compared to determine if there was any difference in the number of complications observed between the two groups.
A retrospective case review of patients presenting for primary codeine dependence from 2009 to 2014. Sixty patients (42F, 36 ± 10 years) using ibuprofen/codeine and 46 (26F, 39 ± 10 years) using paracetamol/codeine containing compound analgesics were compared. A P value of <0.05 was considered significant.
Patients consumed similar daily doses of codeine (699 ± 45 vs. 636 ± 50 mg) with those consuming ibuprofen/codeine containing compound analgesics ingesting twice as many tablets daily (median 60 vs. 30 tablets; P < 0.0001). Complications related to supratherapeutic use of codeine containing compound analgesics occurred more commonly in patients taking ibuprofen/codeine (52/60; 87%) versus paracetamol/codeine compound analgesics (30/46; 65%) (P < 0.01). Patients taking ibuprofen/codeine containing compound analgesics were more likely to have gastrointestinal bleeding (P < 0.05), anaemia (P < 0.0001) and renal tubular acidosis (P < 0.05). There were two deaths in the group abusing ibuprofen/codeine compound analgesics.
In patients with primary codeine dependence, there were more complications related to the supratherapeutic use of ibuprofen/codeine versus paracetamol/codeine containing compound analgesics. The patients in both groups ingested similar total daily codeine amounts. Increased daily tablet intake in the ibuprofen/codeine group could possibly have been linked to lower codeine content per tablet.
本研究旨在比较在因超治疗剂量使用对乙酰氨基酚/可待因或布洛芬/可待因复方镇痛药而出现并发症的原发性可待因依赖患者中,出现并发症的数量是否存在差异。将数据进行比较以确定两组之间观察到的并发症数量是否存在差异。
对 2009 年至 2014 年期间因原发性可待因依赖就诊的患者进行回顾性病例分析。比较使用布洛芬/可待因的 60 例患者(42 例女性,36±10 岁)和使用对乙酰氨基酚/可待因复方镇痛药的 46 例患者(26 例女性,39±10 岁)。P 值<0.05 被认为具有统计学意义。
患者每天摄入的可待因剂量相似(699±45 与 636±50mg),但每天摄入的布洛芬/可待因复方镇痛药的片剂数量是前者的两倍(中位数 60 与 30 片;P<0.0001)。在使用布洛芬/可待因复方镇痛药的患者中,与使用对乙酰氨基酚/可待因复方镇痛药的患者相比,与超治疗剂量使用可待因复方镇痛药相关的并发症更为常见(52/60;87%)(P<0.01)。使用布洛芬/可待因复方镇痛药的患者更有可能出现胃肠道出血(P<0.05)、贫血(P<0.0001)和肾小管性酸中毒(P<0.05)。在滥用布洛芬/可待因复方镇痛药的患者中有两例死亡。
在原发性可待因依赖患者中,与使用对乙酰氨基酚/可待因复方镇痛药相比,因超治疗剂量使用布洛芬/可待因复方镇痛药出现的并发症更多。两组患者每天摄入的总可待因量相似。在布洛芬/可待因组中,每天摄入的片剂数量增加,可能与每片药物中的可待因含量较低有关。